CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed
Drug / intervention
Zoledronic Aciddrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00046254
NCT00046254Phase 3Completed
CompareCT.gov

Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture

Novartis Pharmaceuticals·interventional·Posted Sep 25, 2002·Updated May 2, 2012

In Brief

A Phase 3 clinical trial evaluating Zoledronic Acid for Osteoporosis and Hip Fracture. Completed, across 28 sites in 2 countries.

Detailed Summary

The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoporosis, Hip Fracture
CountriesGermany, United States
Collaborators--

Timeline

Phase 3CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 25, 2002
Enrollment StartFeb 1, 2002
Primary CompletionFeb 1, 2007
TodayJul 2, 2026
Enrollment to primary: 5 yearsPosted 23.8 years ago

Interventions

Zoledronic Aciddrug